Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Pfizer Inc (NYSE:PFE)

31.70
Delayed Data
As of Dec 09
 +0.76 / +2.46%
Today’s Change
28.25
Today|||52-Week Range
37.39
-1.80%
Year-to-Date
Should Big Pharma Be Worried About a Trump Trade War?
6:50am / MotleyFool.com - Paid Partner Content
Pfizer Leukemia Drug Meets Primary Endpoint in Phase III
Dec 06 / Zacks.com - Paid Partner Content
Week in Review: Dow Scores Five Straight Days of Record Closes
Dec 09 / TheStreet.com - Paid Partner Content
Robust Pipeline Supports 5.5% Dividend Yield
Dec 05 / GuruFocus News - Paid Partner Content
US Market Indexes End the Week Higher
Dec 09 / GuruFocus News - Paid Partner Content
2 Stocks That Could Soar Under a Donald Trump Presidency
Dec 05 / MotleyFool.com - Paid Partner Content
Dow, in Another Record Close, Ends With Weekly Gains for Fifth Consecutive Week
Dec 09 / TheStreet.com - Paid Partner Content
Pfizer (PFE) Presents Favorable Data on Leukemia Candidate
Dec 05 / Zacks.com - Paid Partner Content
Stocks on Track for Fresh Records as Health Care Sector Climbs
Dec 09 / TheStreet.com - Paid Partner Content
Does Pfizer Pass Warren Buffetts Test?
Dec 04 / MotleyFool.com - Paid Partner Content
Can Trump Solve Pfizer's $80 Billion Problem?
Dec 09 / MotleyFool.com - Paid Partner Content
Forget Pfizer: Here Are 3 Better Dividend Stocks
Dec 02 / MotleyFool.com - Paid Partner Content
Pharma Stock Roundup: Drug Pricing Heat Back on Sector, Endo, Mylan, AZN to Cut Jobs
Dec 09 / Zacks.com - Paid Partner Content
Merck's Keytruda Gets Priority Review for Hodgkin Lymphoma
Dec 02 / Zacks.com - Paid Partner Content
Pfizer May Be Setting Up as a Low-Risk Buy
Dec 09 / TheStreet.com - Paid Partner Content
Pfizer Offers Positive Phase III Data on Pediatric Epilesy Drug
Dec 02 / Zacks.com - Paid Partner Content
Dow, S&P 500 and Nasdaq Post New Closing Highs as Record-Breaking Run Continues
Dec 08 / TheStreet.com - Paid Partner Content
Why Exelixis Was a Top Stock in 2016 So Far
Dec 02 / MotleyFool.com - Paid Partner Content
Better Buy: Johnson & Johnson vs. Pfizer Inc.
Dec 08 / MotleyFool.com - Paid Partner Content
Pharma Stock Roundup: Nivalis Falls on Study Data, Priority Reviews for Merck's Keytr...
Dec 02 / Zacks.com - Paid Partner Content
Stocks Lose Highs, Dow Still on Track For Record
Dec 08 / TheStreet.com - Paid Partner Content
Here's the Best Dividend Stock in Big Pharma
Dec 01 / MotleyFool.com - Paid Partner Content
Pfizer (PFE) Fined for Price Hike of Anti-Epilepsy Drug in UK
Dec 08 / Zacks.com - Paid Partner Content
5 Top Performing S&P 500 Stocks of November
Dec 01 / Zacks.com - Paid Partner Content
Should Biotech Investors Worry About Donald Trump?
Dec 08 / Zacks.com - Paid Partner Content
Pfizer's Herceptin Biosimilar Meets Primary Endpoint in Study
Dec 01 / Zacks.com - Paid Partner Content
Michael Jordan wins his Chinese name back
Dec 08 / CNNMoney.com
What's Pfizer's Excuse for Not Buying Exelixis?
Nov 30 / MotleyFool.com - Paid Partner Content
Big pharma should beware bite of small watchdogs
Dec 07 / FT.com - Paid Partner Content
ARIAD's Leukemia Drug Iclusig Gets Full Approval in U.S.
Nov 30 / Zacks.com - Paid Partner Content
Pfizer at the Mercy of Trump's Tweets: More Squawk From Jim Cramer
Dec 07 / TheStreet.com - Paid Partner Content
3 High-Yield Dividend Stocks to Buy in December
Nov 30 / MotleyFool.com - Paid Partner Content
Trump warns Wall Street: I'm going to cut drug prices
Dec 07 / CNNMoney.com
J&J (JNJ) Stands Tall in 2016: Reasons for Outperformance
Nov 30 / Zacks.com - Paid Partner Content
Novartis (NVS) Zykadia Positive in Phase III ASCEND-4 Study
Dec 07 / Zacks.com - Paid Partner Content
Pfizer/Merck KGaA: Priority Review for Cancer Drug Avelumab
Nov 30 / Zacks.com - Paid Partner Content
Is Pfizer's New PD-L1 Drug a Game-Changer?
Dec 07 / MotleyFool.com - Paid Partner Content
Merck: Keytruda's Priority Review for New Cancer Indication
Nov 29 / Zacks.com - Paid Partner Content
Frontrunning: December 7
Dec 07 / Investing Channel - Paid Partner Content
The Zacks Analyst Blog Highlights: Pfizer, Microsoft, Priceline, Expedia and United C...
Nov 28 / Zacks.com - Paid Partner Content
Better Buy: Amgen Inc. vs. Pfizer
Dec 07 / MotleyFool.com - Paid Partner Content
J&J (JNJ) Confirms it Approached Actelion for Possible Deal
Nov 28 / Zacks.com - Paid Partner Content
Longest Winning Streak For Global Stocks On Monte Paschi Bailout Hopes, ECB Optimism
Dec 07 / Investing Channel - Paid Partner Content
Trump's Presidency: The Worst Thing Investors Can Do Now
Nov 26 / MotleyFool.com - Paid Partner Content
Pfizer Takes $106 Million Fine from U.K. for Price Hike of Epilepsy Drug
Dec 07 / TheStreet.com - Paid Partner Content
Stunning! Dow hits new high of 19,000 as Trump rally continues
Nov 22 / CNNMoney.com
Pfizer fined 84m for charging 'unfair' price for epilepsy drug
Dec 07 / FT.com - Paid Partner Content
Corporate bond sell-off tests investor appetite
Nov 14 / FT.com - Paid Partner Content
The Latest Buzz in Biotech
Dec 06 / MotleyFool.com - Paid Partner Content
The Trump market rally: Too far, too fast
Nov 14 / CNNMoney.com